HKD3.42
2.40% today
Hong Kong, Apr 08, 10:09 am CET
ISIN
KYG8167W1380
Symbol
1177
Sector
Industry

Sino Biopharmaceutical Target price 2025 - Analyst rating & recommendation

Sino Biopharmaceutical Classifications & Recommendation:

Buy
93%
Hold
7%

Sino Biopharmaceutical Price Target

Target Price HKD4.73
Price HKD3.34
Potential
Number of Estimates 21
21 Analysts have issued a price target Sino Biopharmaceutical 2026 . The average Sino Biopharmaceutical target price is HKD4.73. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 27 analysts: 25 Analysts recommend Sino Biopharmaceutical to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sino Biopharmaceutical stock has an average upside potential 2026 of . Most analysts recommend the Sino Biopharmaceutical stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion HKD 31.30 34.32
8.11% 9.67%
EBITDA Margin 26.04% 25.56%
0.66% 1.83%
Net Margin 6.60% 9.68%
27.32% 46.57%

24 Analysts have issued a sales forecast Sino Biopharmaceutical 2025 . The average Sino Biopharmaceutical sales estimate is

HKD34.3b
Unlock
. This is
9.67% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HKD35.9b 14.85%
Unlock
, the lowest is
HKD32.2b 2.76%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 HKD31.3b 8.11%
2025
HKD34.3b 9.67%
Unlock
2026
HKD37.7b 9.81%
Unlock
2027
HKD41.8b 10.91%
Unlock
2028
HKD34.1b 18.49%
Unlock
2029
HKD38.4b 12.59%
Unlock

16 Analysts have issued an Sino Biopharmaceutical EBITDA forecast 2025. The average Sino Biopharmaceutical EBITDA estimate is

HKD8.8b
Unlock
. This is
7.43% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HKD11.0b 34.53%
Unlock
, the lowest is
HKD6.6b 19.01%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 HKD8.1b 8.82%
2025
HKD8.8b 7.66%
Unlock
2026
HKD9.6b 8.97%
Unlock
2027
HKD10.5b 9.86%
Unlock

EBITDA Margin

2024 26.04% 0.66%
2025
25.56% 1.83%
Unlock
2026
25.36% 0.78%
Unlock
2027
25.12% 0.95%
Unlock

9 Sino Biopharmaceutical Analysts have issued a net profit forecast 2025. The average Sino Biopharmaceutical net profit estimate is

HKD3.3b
Unlock
. This is
60.71% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HKD4.0b 94.23%
Unlock
, the lowest is
HKD2.5b 22.79%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 HKD2.1b 21.43%
2025
HKD3.3b 60.71%
Unlock
2026
HKD3.6b 8.35%
Unlock
2027
HKD3.9b 9.30%
Unlock
2028
HKD2.9b 25.13%
Unlock
2029
HKD3.3b 12.65%
Unlock

Net Margin

2024 6.60% 27.32%
2025
9.68% 46.57%
Unlock
2026
9.55% 1.34%
Unlock
2027
9.41% 1.47%
Unlock
2028
8.65% 8.08%
Unlock
2029
8.65% 0.00%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share HKD 0.11 0.18
21.43% 63.64%
P/E 18.89
EV/Sales 1.97

9 Analysts have issued a Sino Biopharmaceutical forecast for earnings per share. The average Sino Biopharmaceutical EPS is

HKD0.18
Unlock
. This is
63.64% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
HKD0.21 90.91%
Unlock
, the lowest is
HKD0.14 27.27%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 HKD0.11 21.43%
2025
HKD0.18 63.64%
Unlock
2026
HKD0.19 5.56%
Unlock
2027
HKD0.21 10.53%
Unlock
2028
HKD0.16 23.81%
Unlock
2029
HKD0.18 12.50%
Unlock

P/E ratio

Current 31.81 41.00%
2025
18.89 40.62%
Unlock
2026
17.44 7.68%
Unlock
2027
15.95 8.54%
Unlock
2028
21.31 33.61%
Unlock
2029
18.91 11.26%
Unlock

Based on analysts' sales estimates for 2025, the Sino Biopharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.16 3.85%
2025
1.97 8.98%
Unlock
2026
1.79 8.94%
Unlock
2027
1.61 9.84%
Unlock
2028
1.98 22.69%
Unlock
2029
1.76 11.18%
Unlock

P/S ratio

Current 1.95 9.54%
2025
1.78 8.82%
Unlock
2026
1.62 8.93%
Unlock
2027
1.46 9.84%
Unlock
2028
1.80 22.68%
Unlock
2029
1.59 11.18%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today